Roche Liver Disease Panel | May 27, 2026
By combining healthcare algorithms with routine tests, Roche helps healthcare professionals identify patients at risk of chronic liver disease early on, supporting more informed and confident decision-making.
Chronic liver disease (CLD) is a growing global health concern, affecting over 1.5 billion people worldwide.1 It often progresses without symptoms until advanced stages, when liver function is already severely compromised.
To help address this challenge, Roche is combining traditional biomarkers within healthcare algorithms to improve the management of CLD.
Discover navify® Algorithm Suite
The new algorithm panel is a comprehensive library that brings together certified, clinically validated algorithms into navify Algorithm Suite – a single, secure platform. It combines tools like the innovative algorithm LiverPRO for fibrosis risk assessment, ADAPT by with Roche's Elecsys® PRO-C3 for assessing liver fibrosis severity and GAAD with Roche's Elecsys AFP for detecting liver cancer – with trusted clinical tools such as the FIB-4 Index.
Chronic liver disease impacts millions of lives around the world. With the Liver Disease Panel, we are enabling clinicians to identify at-risk patients earlier and help transform liver care to effectively manage patient health.
Roche’s vision is to help clinicians turn insights into actionable, guideline-aligned care. Digital health innovations – such as digital risk stratification tools and advanced data insights – are now helping physicians better manage risk across the CLD pathway.
The new panel is designed for seamless integration into clinical workflows via navify Algorithm Suite. It works with routine blood test results, aligning recommendations with established clinical guidelines. This allows physicians to obtain reliable insights, supporting more personalized care.
Why it matters
Chronic liver disease is a global public health challenge, closely linked to metabolic conditions like metabolic dysfunction-associated steatotic liver disease (MASLD), which now affects 38% of the global population. Left untreated, it can lead to severe complications like cirrhosis or hepatocellular carcinoma (HCC).2
With proactive care, healthcare professionals can potentially improve patient outcomes while optimizing patient referrals which may help reduce the burden on healthcare systems.
Looking ahead
Roche is committed to digital innovation that helps healthcare professionals make more informed care decisions. By identifying risks on time, clinicians can take measures that aim to prevent severe complications like cirrhosis or hepatocellular carcinoma (HCC) before they occur. For patients, this may allow earlier answers, more informed decisions, and better chances at healthier futures.